Achillion Company Description
Achillion Pharmaceuticals is looking for the Achilles heel of infectious disease. The firm is developing biopharmaceutical treatments for infectious diseases, including antiviral treatments for HIV infection and hepatitis C, as well as antibacterials for fighting drug-resistant hospital-based infections. Lead candidate elvucitabine is in clinical trials for the treatment of HIV; the drug is designed specifically for patients who have become resistant to existing antiviral drugs. Achillion is working in collaboration with biotech firm Gilead Sciences to develop a possible treatment for chronic hepatitis C. Another candidate in development is aimed at combating staph and other drug-resistant infections.
View the Comprehensive Company Description for Achillion
The Company Description provides a historical perspective of Achillion's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Achillion's evolution in the marketplace.
